Author

Robert J. Gray

h-index 5 View on Semantic Scholar

We have 3 of 21 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

An AI Model Identifies Chemotherapy Benefit in Node-Negative HR+/HER2- Breast Cancer Patients from TAILORx, a Phase 3 Randomized Clinical Trial

BACKGROUND The prescribing of adjuvant chemotherapy for patients with breast cancer must balance the survival benefit against treatment-related toxicities. TAILORx, a phase 3 randomized clinical trial, demonstrated that endocrine therapy alone was, on average, noninferior to chemoendocrine therapy for patients classifi...

N. Chan, Cerise Tang, D. Biswas et al. · medRxiv · 1 citation

Open access Aug 2026

ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L

Purpose: Mutations in BRAF at codons other than V600 (non-V600) and BRAF fusions confer dependence on RAF-MEK-ERK pathway. Subprotocol Z1L (EAY131-Z1L) investigated the clinical activity of ulixertinib (ERK1/2 inhibitor) in patients with tumors harboring these alterations. Patients and Methods: In this single-arm study...

Vivek Subbiah, Feng-Min Zhao, R. Kudchadkar et al. · Clinical Cancer Research · 0 citations

Open access Aug 2026

Associations of Age With Tumor Genomic Characteristics in Relapsed/Refractory Cancers Interrogated With the NCI-MATCH Trial Targeted Gene Panel Assay

PURPOSE Motivated by the rising incidence of cancers at younger ages, this study compares tumor genomic alterations between adolescents and young adults (AYAs; 18-39 years) and non-AYAs (40 years and older) and explores the relationship with continuous age in patients with relapsed/refractory ovarian, breast, and color...

Hari Sankaran, Yuri Kotliarov, Ying-Dong Zhao et al. · JCO Precision Oncology · 0 citations